Simple view
Full metadata view
Authors
Statistics
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3) : a double-blind, randomised, placebo-controlled, phase 3 trial
Journal
The Lancet Oncology
200
Author
Volume
22
Number
5
Pages
678-689
ISSN
1470-2045
eISSN
1474-5488
Access date
2022-02-01
Language
English
Journal language
English
Affiliation
Wydział Lekarski : Klinika Hematologii
Scopus© citations
111
dc.affiliation | Wydział Lekarski : Klinika Hematologii | pl |
dc.cm.date | 2022-04-08T06:12:13Z | |
dc.cm.id | 103923 | pl |
dc.cm.idOmega | UJCM0083b6986a9a4534bd32e0d87f3718bb | pl |
dc.contributor.author | Matasar, Matthew J. | pl |
dc.contributor.author | Capra, Marcelo | pl |
dc.contributor.author | Özcan, Muhit | pl |
dc.contributor.author | Lv, Fangfang | pl |
dc.contributor.author | Li, Wei | pl |
dc.contributor.author | Yanez, Eduardo | pl |
dc.contributor.author | Sapunarova, Katya | pl |
dc.contributor.author | Lin, Tongyu | pl |
dc.contributor.author | Jin, Jie | pl |
dc.contributor.author | Jurczak, Wojciech - 129923 | pl |
dc.contributor.author | Hamed, Aryan | pl |
dc.contributor.author | Wang, Ming-Chung | pl |
dc.contributor.author | Baker, Ross | pl |
dc.contributor.author | Bondarenko, Igor | pl |
dc.contributor.author | Zhang, Qingyuan | pl |
dc.contributor.author | Feng, Jifeng | pl |
dc.contributor.author | Geissler, Klaus | pl |
dc.contributor.author | Lazaroiu, Mihaela | pl |
dc.contributor.author | Saydam, Guray | pl |
dc.contributor.author | Szomor, Árpád | pl |
dc.contributor.author | Bouabdallah, Krimo | pl |
dc.contributor.author | Galiulin, Rinat | pl |
dc.contributor.author | Uchida, Toshiki | pl |
dc.contributor.author | Soler, Lidia Mongay | pl |
dc.contributor.author | Cao, Anjun | pl |
dc.contributor.author | Hiemeyer, Florian | pl |
dc.contributor.author | Mehra, Aruna | pl |
dc.contributor.author | Childs, Barrett H. | pl |
dc.contributor.author | Shi, Yuankai | pl |
dc.contributor.author | Zinzani, Pier Luigi | pl |
dc.date.accession | 2022-02-01 | pl |
dc.date.accessioned | 2022-04-08T06:12:13Z | |
dc.date.available | 2022-04-08T06:12:13Z | |
dc.date.issued | 2021 | pl |
dc.description.number | 5 | pl |
dc.description.physical | 678-689 | pl |
dc.description.volume | 22 | pl |
dc.identifier.doi | 10.1016/S1470-2045(21)00145-5 | pl |
dc.identifier.eissn | 1474-5488 | pl |
dc.identifier.issn | 1470-2045 | pl |
dc.identifier.uri | https://ruj.uj.edu.pl/xmlui/handle/item/289981 | |
dc.language | eng | pl |
dc.language.container | eng | pl |
dc.rights | Dodaję tylko opis bibliograficzny | * |
dc.rights.licence | Bez licencji otwartego dostępu | |
dc.rights.uri | * | |
dc.subtype | Article | pl |
dc.title | Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3) : a double-blind, randomised, placebo-controlled, phase 3 trial | pl |
dc.title.journal | The Lancet Oncology | pl |
dc.type | JournalArticle | pl |
dspace.entity.type | Publication |
dc.affiliationpl
Wydział Lekarski : Klinika Hematologii dc.cm.date
2022-04-08T06:12:13Z dc.cm.idpl
103923 dc.cm.idOmegapl
UJCM0083b6986a9a4534bd32e0d87f3718bb dc.contributor.authorpl
Matasar, Matthew J. dc.contributor.authorpl
Capra, Marcelo dc.contributor.authorpl
Özcan, Muhit dc.contributor.authorpl
Lv, Fangfang dc.contributor.authorpl
Li, Wei dc.contributor.authorpl
Yanez, Eduardo dc.contributor.authorpl
Sapunarova, Katya dc.contributor.authorpl
Lin, Tongyu dc.contributor.authorpl
Jin, Jie dc.contributor.authorpl
Jurczak, Wojciech - 129923 dc.contributor.authorpl
Hamed, Aryan dc.contributor.authorpl
Wang, Ming-Chung dc.contributor.authorpl
Baker, Ross dc.contributor.authorpl
Bondarenko, Igor dc.contributor.authorpl
Zhang, Qingyuan dc.contributor.authorpl
Feng, Jifeng dc.contributor.authorpl
Geissler, Klaus dc.contributor.authorpl
Lazaroiu, Mihaela dc.contributor.authorpl
Saydam, Guray dc.contributor.authorpl
Szomor, Árpád dc.contributor.authorpl
Bouabdallah, Krimo dc.contributor.authorpl
Galiulin, Rinat dc.contributor.authorpl
Uchida, Toshiki dc.contributor.authorpl
Soler, Lidia Mongay dc.contributor.authorpl
Cao, Anjun dc.contributor.authorpl
Hiemeyer, Florian dc.contributor.authorpl
Mehra, Aruna dc.contributor.authorpl
Childs, Barrett H. dc.contributor.authorpl
Shi, Yuankai dc.contributor.authorpl
Zinzani, Pier Luigi dc.date.accessionpl
2022-02-01 dc.date.accessioned
2022-04-08T06:12:13Z dc.date.available
2022-04-08T06:12:13Z dc.date.issuedpl
2021 dc.description.numberpl
5 dc.description.physicalpl
678-689 dc.description.volumepl
22 dc.identifier.doipl
10.1016/S1470-2045(21)00145-5 dc.identifier.eissnpl
1474-5488 dc.identifier.issnpl
1470-2045 dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/289981 dc.languagepl
eng dc.language.containerpl
eng dc.rights*
Dodaję tylko opis bibliograficzny dc.rights.licence
Bez licencji otwartego dostępu dc.rights.uri*
dc.subtypepl
Article dc.titlepl
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3) : a double-blind, randomised, placebo-controlled, phase 3 trial dc.title.journalpl
The Lancet Oncology dc.typepl
JournalArticle dspace.entity.type
Publication Affiliations
No affiliation
Matasar, Matthew J.
Capra, Marcelo
Özcan, Muhit
Lv, Fangfang
Li, Wei
Yanez, Eduardo
Sapunarova, Katya
Lin, Tongyu
Jin, Jie
Jurczak, Wojciech
Hamed, Aryan
Wang, Ming-Chung
Baker, Ross
Bondarenko, Igor
Zhang, Qingyuan
Feng, Jifeng
Geissler, Klaus
Lazaroiu, Mihaela
Saydam, Guray
Szomor, Árpád
Bouabdallah, Krimo
Galiulin, Rinat
Uchida, Toshiki
Soler, Lidia Mongay
Cao, Anjun
Hiemeyer, Florian
Mehra, Aruna
Childs, Barrett H.
Shi, Yuankai
Zinzani, Pier Luigi
* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.
Views
15
Views per month
Views per city
Ashburn
2
Bad Griesbach
2
Wroclaw
2
Dublin
1
Gorzów Wielkopolski
1
Krakow
1
Tokyo
1
No access
No Thumbnail Available